Effects of dynamic contrast enhancement on transition zone prostate cancer in Prostate Imaging Reporting and Data System Version 2.1

1Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-49. doi: 10.3322/caac.21660Sung H Ferlay J Siegel RL Laversanne M Soerjomataram I Jemal A et al Global Cancer Statistics 2020 GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 2021 71 209 49 10.3322/caac.2166033538338Open DOISearch in Google Scholar

2Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021; 71: 7-33. doi: 10.3322/caac.21654Siegel RL Miller KD Fuchs HE Jemal A Cancer Statistics, 2021 CA Cancer J Clin 2021 71 7 33 10.3322/caac.2165433433946Open DOISearch in Google Scholar

3Teoh J, Hirai H W, Ho J, Chan F, Tsoi K, Ng C. Global incidence of prostate cancer in developing and developed countries with changing age structures. PLoS One 2019; 14: e221775. doi: 10.1371/journal.pone.0221775Teoh J Hirai H W Ho J Chan F Tsoi K Ng C Global incidence of prostate cancer in developing and developed countries with changing age structures PLoS One 2019 14 e221775 10.1371/journal.pone.0221775681281231647819Open DOISearch in Google Scholar

4Turkbey B, Brown AM, Sankineni S, Wood BJ, Pinto PA, Choyke PL. Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer. CA Cancer J Clin 2016; 66: 326-36. doi: 10.3322/caac.21333Turkbey B Brown AM Sankineni S Wood BJ Pinto PA Choyke PL Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer CA Cancer J Clin 2016 66 326 36 10.3322/caac.21333751197926594835Open DOISearch in Google Scholar

5Ueno Y, Tamada T, Bist V, Reinhold C, Miyake H, Tanaka U, et al. Multiparametric magnetic resonance imaging: current role in prostate cancer management. Int J Urol 2016; 23: 550-7. doi: 10.1111/iju.13119Ueno Y Tamada T Bist V Reinhold C Miyake H Tanaka U et al Multiparametric magnetic resonance imaging: current role in prostate cancer management Int J Urol 2016 23 550 7 10.1111/iju.1311927184019Open DOISearch in Google Scholar

6Litjens G, Elliott R, Shih N, Feldman M, Kobus T, Kaa C, et al. Computer-extracted features can distinguish noncancerous confounding disease from prostatic adenocarcinoma at multiparametric MR imaging. Radiology 2016; 278: 135-45. doi: 10.1148/radiol.201514285Litjens G Elliott R Shih N Feldman M Kobus T Kaa C et al Computer-extracted features can distinguish noncancerous confounding disease from prostatic adenocarcinoma at multiparametric MR imaging Radiology 2016 278 135 45 10.1148/radiol.201514285Open DOISearch in Google Scholar

7Remmers S, Roobol M J. Personalized strategies in population screening for prostate cancer. Int J Cancer 2020; 147: 2977-87. doi: 10.1002/ijc.33045Remmers S Roobol M J Personalized strategies in population screening for prostate cancer Int J Cancer 2020 147 2977 87 10.1002/ijc.33045758698032394421Open DOISearch in Google Scholar

8Barentsz JO, Richenberg J, Clements R, Choyke P, Verma S, Villeirs G, et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012; 22: 746-57. doi: 10.1007/s00330-011-2377-y. 9Barentsz JO Richenberg J Clements R Choyke P Verma S Villeirs G et al ESUR prostate MR guidelines 2012 Eur Radiol 2012 22 746 57 10.1007/s00330-011-2377-y.9Open DOISearch in Google Scholar

9Gupta RT, Mehta KA, Turkbey B, Verma S. PI-RADS: past, present, and future. J Magn Reson Imaging 2020; 52: 33-53. doi: 10.1002/jmri.26896Gupta RT Mehta KA Turkbey B Verma S PI-RADS: past, present, and future J Magn Reson Imaging 2020 52 33 53 10.1002/jmri.2689631397038Open DOISearch in Google Scholar

10Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2. Eur Urol 2019; 76: 340-51. doi: 10.1016/j.eururo.2019.02.033Turkbey B Rosenkrantz AB Haider MA Padhani AR Villeirs G Macura KJ et al Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2 Eur Urol 2019 76 340 51 10.1016/j.eururo.2019.02.03330898406Open DOISearch in Google Scholar

11Gatti M, Faletti R, Calleris G, Giglio J, Berzovini C, Gentile F, et al. Prostate cancer detection with biparametric magnetic resonance imaging (bpMRI) by readers with different experience: performance and comparison with multiparametric (mpMRI). Abdom Radiol 2019; 44: 1883-93. doi: 10.1007/ s00261-019-01934-3Gatti M Faletti R Calleris G Giglio J Berzovini C Gentile F et al Prostate cancer detection with biparametric magnetic resonance imaging (bpMRI) by readers with different experience: performance and comparison with multiparametric (mpMRI) Abdom Radiol 2019 44 1883 93 10.1007/s00261-019-01934-330788558Open DOISearch in Google Scholar

12Wassberg C, Akin O, Vargas HA, Dave AS, Zhang Jb, Hricak H. The incremental value of contrast-enhanced MRI in the detection of biopsy-proven local recurrence of prostate cancer after radical prostatectomy: effect of reader experience. AJR Am J Roentgenol 2012; 199: 360-6. doi: 10.2214/ AJR.11.6923Wassberg C Akin O Vargas HA Dave AS Jb Zhang H Hricak The incremental value of contrast-enhanced MRI in the detection of biopsy-proven local recurrence of prostate cancer after radical prostatectomy: effect of reader experience AJR Am J Roentgenol 2012 199 360 6 10.2214/AJR.11.6923346207522826397Open DOISearch in Google Scholar

13Tamada T, Sone T, Jo Y, Hiratsuka J, Higaki A, Higashi H, et al. Locally recurrent prostate cancer after high- dose-rate brachytherapy: the value of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2- weighted imaging in localizing tumors. AJR Am J Roentgenol 2011; 197: 408-14. doi: 10.2214/AJR.10.5772Tamada T Sone T Jo Y Hiratsuka J Higaki A Higashi H et al Locally recurrent prostate cancer after high- dose-rate brachytherapy: the value of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2- weighted imaging in localizing tumors AJR Am J Roentgenol 2011 197 408 14 10.2214/AJR.10.577221785087Open DOISearch in Google Scholar

14Kuhl CK, Bruhn R, Krämer N, Nebelung S, Heidenreich A, Schrading S. Abbreviated biparametric prostate MR imaging in men with elevated prostate-specific antigen. Radiology 2017; 285: 493-505. doi: 10.1148/ radiol.2017170129Kuhl CK Bruhn R Krämer N Nebelung S Heidenreich A Schrading S Abbreviated biparametric prostate MR imaging in men with elevated prostate-specific antigen Radiology 2017 285 493 505 10.1148/radiol.201717012928727544Open DOISearch in Google Scholar

15Junker D, Steinkohl F, Fritz V, Bektic J, Tokas T, Aigner F, et al. Comparison of multiparametric and biparametric MRI of the prostate: are gadolinium-based contrast agents needed for routine examinations? World J Urol 2019; 37: 691-9. doi: 10.1007/s00345-018-2428-yJunker D Steinkohl F Fritz V Bektic J Tokas T Aigner F et al Comparison of multiparametric and biparametric MRI of the prostate: are gadolinium-based contrast agents needed for routine examinations? World J Urol 2019 37 691 9 10.1007/s00345-018-2428-y30078170Open DOISearch in Google Scholar

16Di Campli E, Delli P A, Seccia B, Cianci R, d’Annibale M, Colasante A, et al. Diagnostic accuracy of biparametric vs multiparametric MRI in clinically significant prostate cancer: comparison between readers with different experience. Eur J Radiol 2018; 101: 17-23. doi: 10.1016/j.ejrad.2018.01.028Di Campli E Delli P A Seccia B Cianci R d’Annibale M Colasante A et al Diagnostic accuracy of biparametric vs multiparametric MRI in clinically significant prostate cancer: comparison between readers with different experience Eur J Radiol 2018 101 17 23 10.1016/j.ejrad.2018.01.02829571792Open DOISearch in Google Scholar

17Huebner NA, Korn S, Resch I, Grubmüller B, Gross T, Gale R, et al. Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)-do we still need contrast media? Eur Radiol 2021; 31: 3754-64. doi: 10.1007/s00330-020-07494-1Huebner NA Korn S Resch I Grubmüller B Gross T Gale R et al Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)-do we still need contrast media? Eur Radiol 2021 31 3754 64 10.1007/s00330-020-07494-1812874933263793Open DOISearch in Google Scholar

18Epstein JI, Amin MB, Reuter VE, Humphrey PA. Contemporary Gleason grading of prostatic carcinoma: an update with discussion on practical issues to implement the 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2017; 41: e1-7. doi: 10.1097/PAS.0000000000000820Epstein JI Amin MB Reuter VE Humphrey PA Contemporary Gleason grading of prostatic carcinoma: an update with discussion on practical issues to implement the 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason Grading of Prostatic Carcinoma Am J Surg Pathol 2017 41 e1 7 10.1097/PAS.000000000000082028177964Open DOISearch in Google Scholar

19Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol 2016; 69: 16-40. doi: 10.1016/j.eururo.2015.08.05Weinreb JC Barentsz JO Choyke PL Cornud F Haider MA Macura KJ et al PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2 Eur Urol 2016 69 16 40 10.1016/j.eururo.2015.08.05Open DOISearch in Google Scholar

20Oishi M, Shin T, Ohe C, Nassiri N, Palmer SL, Aron M, et al. Which patients with negative magnetic resonance imaging can safely avoid biopsy for prostate cancer? J Urol 2019; 201: 268-76. doi: 10.1016/j.juro.2018.08.046Oishi M Shin T Ohe C Nassiri N Palmer SL Aron M et al Which patients with negative magnetic resonance imaging can safely avoid biopsy for prostate cancer? J Urol 2019 201 268 76 10.1016/j.juro.2018.08.046667726430189186Open DOISearch in Google Scholar

21Tamada T, Kido A, Yamamoto A, Takeuchi M, Miyaji Y, Moriya T, et al. Comparison of biparametric and multiparametric MRI for clinically significant prostate cancer detection with PI-RADS version 2.1. J Magn Reson Imaging 2021; 53: 283-91. doi: 10.1002/jmri.27283Tamada T Kido A Yamamoto A Takeuchi M Miyaji Y Moriya T et al Comparison of biparametric and multiparametric MRI for clinically significant prostate cancer detection with PI-RADS version 2.1 J Magn Reson Imaging 2021 53 283 91 10.1002/jmri.27283Open DOISearch in Google Scholar

22Taghipour M, Ziaei A, Alessandrino F, Hassanzadeh E, Harisinghani M, Vangel M, et al. Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy. Abdom Radiol 2019; 44: 1520-7. doi: 10.1007/s00261-018-1807-6Taghipour M Ziaei A Alessandrino F Hassanzadeh E Harisinghani M Vangel M et al Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy Abdom Radiol 2019 44 1520 7 10.1007/s00261-018-1807-6Open DOISearch in Google Scholar

23Engelbrecht MR, Huisman HJ, Laheij RJ, Jager GJ, van Leenders GJ, Hulsbergen-Van De Kaa CA, et al. Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging. Radiology 2003; 229: 248-54. doi: 10.1148/ radiol.2291020200Engelbrecht MR Huisman HJ Laheij RJ Jager GJ van Leenders GJ Hulsbergen-Van De Kaa CA et al Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging Radiology 2003 229 248 54 10.1148/radiol.2291020200Open DOISearch in Google Scholar

24Nicholson B, Theodorescu D. Angiogenesis and prostate cancer tumor growth. J Cell Biochem 2004; 91: 125- 50. doi: 10.1002/jcb.10772Nicholson B Theodorescu D Angiogenesis and prostate cancer tumor growth J Cell Biochem 2004 91 125 50 10.1002/jcb.10772Open DOISearch in Google Scholar

25Verma S, Turkbey B, Muradyan N, Rajesh A, Cornud F, Haider MA, et al. Overview of dynamic contrast- enhanced MRI in prostate cancer diagnosis and management. AJR Am J Roentgenol 2012; 198: 1277-88. doi: 10.2214/ AJR.12.8510Verma S Turkbey B Muradyan N Rajesh A Cornud F Haider MA et al Overview of dynamic contrast- enhanced MRI in prostate cancer diagnosis and management AJR Am J Roentgenol 2012 198 1277 88 10.2214/AJR.12.8510Open DOISearch in Google Scholar

26Sanz-Requena R, Martí-Bonmatí L, Pérez-Martínez R, García-Martí G. Dynamic contrast-enhanced case- control analysis in 3T MRI of prostate cancer can help to characterize tumor aggressiveness. Eur J Radiol 2016; 85: 2119-26. doi: 10.1016/j.ejrad.2016.09.022Sanz-Requena R Martí-Bonmatí L, Pérez-Martínez R, García-Martí G. Dynamic contrast-enhanced case- control analysis in 3T MRI of prostate cancer can help to characterize tumor aggressiveness Eur J Radiol 2016 85 2119 26 10.1016/j.ejrad.2016.09.022Open DOISearch in Google Scholar